Project Grant R00HL168224
Award Date
7/15/24
Completion Date
6/30/27
Dollars Obligated
$677K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This National Science Foundation (NSF) project grant, awarded under the Biological Sciences program (CFDA 47.074), will provide $1,225,175.00 to support a 3-year study at Wayne State University on the adaptation of the cytochrome c oxidase enzyme in response to hypoxic (low oxygen) conditions in systemic vascular cells. The key objectives are to: 1) characterize the dynamic regulation of cytochrome c oxidase subunit isoform composition in systemic pericytes and vascular cells under chronic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $735,939 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and validate new technologies for accurate, rapid, and high-frequency blood gas analysis. The key products and services to be delivered through this funding include: Creation of a miniaturized, automated device that attaches to a standard...
This federal Project Grant award of $762,405.80 from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the cellular and molecular mechanisms by which cell-free hemoglobin (CFH) and oxidized low-density lipoprotein (oxLDL) contribute to microvascular hyperpermeability and lung injury during sepsis. The research will focus on understanding how CFH-induced oxidation of LDL leads to the activation of the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,753.90 in funding to Bloodworks (also known as Puget Sound Blood Center and Program) to investigate the role of thiol isomerases in promoting redox-sensitive vaso-occlusion in sickle cell disease. The award period is from August 1, 2024 to July 31, 2027. The research aims to mechanistically examine how thiol isomerases,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $744,305 to the University of Virginia to conduct research on the role of the transcription factor PHOX2B in maintaining the molecular, cellular, and network properties of intrinsically CO2/H+-sensitive retrotrapezoid nucleus (RTN) neurons. The research aims to: Examine how persistent expression of wild-type and CCHS-relevant...
This $707,410 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports a research initiative titled "OVERCOMING INEQUITIES IN PULSE OXIMETRY THROUGH CLINICAL INFORMATICS (OPTIC)". The key products and services to be delivered include: Developing machine learning models to predict which patients are at high risk for "hidden hypoxemia" - when pulse oximetry...
This $231,207 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop next-generation laser technology to improve the efficiency and clinical viability of hyperpolarized xenon-129 magnetic resonance imaging (MRI) for functional pulmonary imaging. The project will investigate the use of ultra-narrow bandwidth lasers to optimize the spin-exchange optical pumping process required to generate hyperpolarized xenon-129...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $483,852 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a high-throughput platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to enable the optimization of emerging sickle cell disease...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $234,000.00 to the University of Colorado-Denver to engineer "hemostatic red blood cells" targeted to collagen and fibrin for use in stopping severe, non-compressible hemorrhage. The project aims to develop this novel approach to enhance clot formation and stability, with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,138,502 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Rector & Visitors of the University of Virginia. The grant will fund research to investigate the mechanistic roles of the enzymes NQO1 and NQO2 in primaquine-induced hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient red blood cells. The research will utilize novel mouse models and employ in vitro and in vivo...